-

Medincell to Join the Euronext SBF 120 Index

MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Paris:MEDCL) joins the Euronext SBF 120 index, which includes the 120 largest companies listed on Euronext Paris, including the CAC 40 and most of the key players in the French economy. Medincell joins also the CAC Mid 60 index.

Christophe Douat, CEO of Medincell, said: “Just six years after our IPO, Medincell joins the SBF 120, a recognition of our strength and performance. This milestone enhances our attractiveness to new French and international institutional investors and will increase our visibility among financial analysts and the media. This distinction should lead to greater trading volume in our shares. I would like to thank Medincell's employees - who are all shareholders, and all our individual and institutional shareholders for their confidence. This new step is the result of their ongoing support.”

The composition of the SBF 120 and CAC Mid 60 is decided by Euronext's Scientific Council for Indices on the basis of the market capitalizations and liquidity (trading volume) of companies listed on Euronext Paris.

Medincell's inclusion in the index will be effective from 20 December, after market close.

The SBF 120 index includes the following companies listed on Euronext Paris:

List of companies in the SBF 120 index: https://live.euronext.com/fr/product/indices/FR0003999481-XPAR

List of companies in the CAC Mid 60 index: https://live.euronext.com/fr/product/indices/QS0010989117-XPAR

Euronext press release: https://www.euronext.com/en/about/media/euronext-press-releases/euronext-announces-december-2024-quarterly-review-results-cacr

Contacts

David Heuzé
Head of Corporate and Financial Communications, and ESG
david.heuze@Medincell.com / +33 (0)6 83 25 21 86

Grace Kim
Head of US Financial Strategy & IR
grace.kim@Medincell.com / +1 (646) 991-4023

Nicolas Mérigeau/Arthur Rouillé
Media Relations
Medincell@newcap.eu / +33 (0)1 44 71 94 94

Louis-Victor Delouvrier/Alban Dufumier
Investor Relations France
Medincell@newcap.eu / +33 (0)1 44 71 94 94

Industry:

Medincell

BOURSE:MEDCL
Release Versions
English

Contacts

David Heuzé
Head of Corporate and Financial Communications, and ESG
david.heuze@Medincell.com / +33 (0)6 83 25 21 86

Grace Kim
Head of US Financial Strategy & IR
grace.kim@Medincell.com / +1 (646) 991-4023

Nicolas Mérigeau/Arthur Rouillé
Media Relations
Medincell@newcap.eu / +33 (0)1 44 71 94 94

Louis-Victor Delouvrier/Alban Dufumier
Investor Relations France
Medincell@newcap.eu / +33 (0)1 44 71 94 94

More News From Medincell

Medincell: Videoconference and Publication of Half-year Financial Results, Tuesday, December 9, 2025

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL) will hold a videoconference on Tuesday December 9, 2025 to present the half-year financial results (April 2025-September 2025) > Meeting in French, 6:00 pm (CET): https://www.medincell.com/fr/live-fr/ > Meeting in English, 7:00 pm (CET): https://www.medincell.com/live-en/ Shareholders are invited to send their questions to communication@medincell.com, or through the chat system during the videoconference. About...

Medincell Management to Present at the 8th Annual Evercore Healthcare Conference and at the Piper Sandler 37th Annual Healthcare Conference

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL): Christophe Douat, Chief Executive Officer, Dr. Richard Malamut, Chief Medical Officer, and Dr Grace Kim, Chief Strategy Officer, U.S. Finance, will participate at the following conferences in December: 8th Annual Evercore Healthcare Conference (Miami, Dec. 2-4) Fireside chat on Wednesday, December 3, 2025, at 9:35am ET (3:35pm CET) Live webcast and replay: https://wsw.com/webcast/evercore52/medcl/2521706 Piper Sandl...

Medincell Awarded New Grant to Fight Malaria

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL): Quiterie de Beauregard, Head of Global Health at Medincell, said: “On top of previous studies, our program is now backed by a recent large-scale human field study which has shown that oral ivermectin can significantly reduce malaria transmission - by about 26% - during mass drug administration campaigns by neutralizing disease-vector mosquitoes.2 However, the study also highlighted substantial logistical challenges...
Back to Newsroom